{"name":"Valneva Austria GmbH","slug":"valneva-austria-gmbh","ticker":"","exchange":"","domain":"valnevaaustriagmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Biological Vaccine VLA1553","genericName":"Biological Vaccine VLA1553","slug":"biological-vaccine-vla1553","indication":"Prevention of chikungunya virus infection in at-risk populations and travelers","status":"phase_3"},{"name":"VLA2001 - adolescent part","genericName":"VLA2001 - adolescent part","slug":"vla2001-adolescent-part","indication":"COVID-19 prevention in adolescents","status":"phase_3"},{"name":"Havrix®720","genericName":"Havrix®720","slug":"havrix720","indication":"Prevention of hepatitis A infection in adults and children","status":"phase_3"},{"name":"IC51","genericName":"IC51","slug":"ic51","indication":"Cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV infection","status":"phase_3"},{"name":"VLA1553","genericName":"VLA1553","slug":"vla1553","indication":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Japanese Encephalitis purified inactivated vaccine","genericName":"Japanese Encephalitis purified inactivated vaccine","slug":"japanese-encephalitis-purified-inactivated-vaccine","indication":"Prevention of Japanese encephalitis in at-risk populations and travelers","status":"phase_3"},{"name":"IC41","genericName":"IC41","slug":"ic41","indication":"Other","status":"phase_2"},{"name":"IC51 Japanese Encephalitis","genericName":"IC51 Japanese Encephalitis","slug":"ic51-japanese-encephalitis","indication":"Prevention of Japanese encephalitis in adults and children","status":"phase_3"},{"name":"Live-attenuated CHIKV vaccine VLA1553","genericName":"Live-attenuated CHIKV vaccine VLA1553","slug":"live-attenuated-chikv-vaccine-vla1553","indication":"Chikungunya","status":"phase_2"}]}],"pipeline":[{"name":"Biological Vaccine VLA1553","genericName":"Biological Vaccine VLA1553","slug":"biological-vaccine-vla1553","phase":"phase_3","mechanism":"VLA1553 is an inactivated chikungunya virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against chikungunya virus infection.","indications":["Prevention of chikungunya virus infection in at-risk populations and travelers"],"catalyst":""},{"name":"Japanese Encephalitis purified inactivated vaccine","genericName":"Japanese Encephalitis purified inactivated vaccine","slug":"japanese-encephalitis-purified-inactivated-vaccine","phase":"phase_3","mechanism":"This inactivated vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","indications":["Prevention of Japanese encephalitis in at-risk populations and travelers"],"catalyst":""},{"name":"VLA2001 - adolescent part","genericName":"VLA2001 - adolescent part","slug":"vla2001-adolescent-part","phase":"phase_3","mechanism":"VLA2001 is a COVID-19 vaccine that uses a recombinant, replication-incompetent chimpanzee adenovirus vector to express the SARS-CoV-2 spike protein.","indications":["COVID-19 prevention in adolescents"],"catalyst":""},{"name":"Havrix®720","genericName":"Havrix®720","slug":"havrix720","phase":"phase_3","mechanism":"Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","indications":["Prevention of hepatitis A infection in adults and children"],"catalyst":""},{"name":"IC41","genericName":"IC41","slug":"ic41","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IC51","genericName":"IC51","slug":"ic51","phase":"phase_3","mechanism":"IC51 is a therapeutic vaccine that stimulates the immune system to recognize and attack cells infected with human papillomavirus (HPV).","indications":["Cervical intraepithelial neoplasia (CIN) 2/3 associated with HPV infection"],"catalyst":""},{"name":"IC51 Japanese Encephalitis","genericName":"IC51 Japanese Encephalitis","slug":"ic51-japanese-encephalitis","phase":"phase_3","mechanism":"IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","indications":["Prevention of Japanese encephalitis in adults and children"],"catalyst":""},{"name":"Live-attenuated CHIKV vaccine VLA1553","genericName":"Live-attenuated CHIKV vaccine VLA1553","slug":"live-attenuated-chikv-vaccine-vla1553","phase":"phase_2","mechanism":"Live-attenuated CHIKV vaccine targets the Chikungunya virus","indications":["Chikungunya"],"catalyst":""},{"name":"VLA1553","genericName":"VLA1553","slug":"vla1553","phase":"phase_3","mechanism":"VLA1553 is a COVID-19 vaccine.","indications":["Prevention of COVID-19 disease caused by SARS-CoV-2 virus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-08-26","type":"regulatory","source":"Medical Dialogues","summary":"USFDA Suspends Ixchiq Chikungunya Vaccine License Citing Encephalitis Death, 20+ Serious Adverse Events - Medical Dialogues","headline":"USFDA Suspends Ixchiq Chikungunya Vaccine License Citing Encephalitis Death, 20+ Serious Adverse Events","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNOW8yMTRkWjJMUS1kY25JM3NPVlpMaURLT1ZNYWdBTFQxMko3QzBmQ2hLc0M3MzdkQ0xLYlN5U3gySjQzVlA2ZGRWSGh3bG5IanpRVFRTNUdHWWtHM21Mc3VtYTFTZVQ4a0VQV184cG5LOHJ1ZjNHZGZDbnZTZEZPRXR4ZUMwaE5VR3REMUgzMFpiYmpCNFA1MXgyUzMxQdIBVkFVX3lxTE5RNkhkSXhZMnVUTEpzcU9MbkhxZnRwMm9Benp4ajlDcGdlZWVqSmo5d0NYVWlLb1g3aV9wLVFqbUtXUVowS3k4MEJJb093Y3gzdXJSNGxn?oc=5","date":"2025-08-15","type":"pipeline","source":"Law360","summary":"Stewart Issues Dozens More Discretionary Denial Decisions - Law360","headline":"Stewart Issues Dozens More Discretionary Denial Decisions - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOOGxzQ09FUi1Wdm0yRW5wT0IzVVl5NEo1cGJPSjNrLVRjQWRPeXJUcXFSUzloTjNSSElyNzlEenpFWFFqN2hPN0pBMGIzM2lmZTRQc0ZWWVhGcGxNMlBZTXU2cUNjMklaVUhtNEJtSlg3ZU85N3hudnpmM01MWDVjZDdWVlZKVFJNdXl1OEhMRk9xTmZCVVZVTjUwYzF0ZzBkQWV1bXN6b0NiMXdDQm4tcA?oc=5","date":"2024-05-31","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024 - European Medicines Ag","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOa0o1WnpaYkUtMURjQzJobTQ1R0drOUs1U3A2SnRCcU9MNk9JQ29hUll4NjFGZm53TXc1ZWNSOE9JdllWVEl6cjJ0YUpJX1pGbENaZ3Iybl9Ebjl0Rl9ZYUNiZW9uTmdwMjYwWHA2bVkyLXRmUk9pZlpsdXg5UExNclFhaDVhT0N0S1dTYWJUQWhkRmNaV21MQS1IeS0wcHBuTWc?oc=5","date":"2023-05-20","type":"pipeline","source":"Paul-Ehrlich-Institut","summary":"COVID-19 Vaccine Valneva (Inactivated, Adjuvanted) – Shelf Life Extended to 15 Months - Paul-Ehrlich-Institut","headline":"COVID-19 Vaccine Valneva (Inactivated, Adjuvanted) – Shelf Life Extended to 15 Months - Paul-Ehrlich","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNYk1zZTlEY0dMQ2VkTGNxay01c21waV9VSVRlZ2hHSTROZERRemlhUHZ3VERiR1ZSX0JTZEpOMkdZd2pOdjRNdTBvVVhWaktrTy1JUHZtd1RVaWIwZU56Q2NtWkhqRVpwVjJ6RDlLeF9NLTB6R0tXbWh5RjJ4ZWVNOWlLZGpVVy15QWNF?oc=5","date":"2022-12-06","type":"pipeline","source":"Paul-Ehrlich-Institut","summary":"COVID-19 Vaccine Valneva (Inactivated, Adjuvanted) – Shelf Life Extended to 18 Months - Paul-Ehrlich-Institut","headline":"COVID-19 Vaccine Valneva (Inactivated, Adjuvanted) – Shelf Life Extended to 18 Months - Paul-Ehrlich","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdVJURnp1MlhjRTZ4Z0tmdTdwczJjaWlJYXV2UG10RHJPTmYyM0h6VG5qR0hVdHZPbjZxbnBBZzA3TFBkaDFzcV9zQmF2Mlk3ajVuZU80Qk5lSVpRQUNLRjdFeC1DaWo2VXRxUFJiUk95X1RabUd2NXctZmk2MzBvcXV1eUMteXIwZU80cDhCNG5pZW1XLXJjcG1KNlhWNVlUN3U2eVJYWTU1M2Y2ckE?oc=5","date":"2022-08-17","type":"pipeline","source":"Pharmaceutical Technology","summary":"Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape - Pharmaceutical Technology","headline":"Valneva’s Lyme disease vaccine faces final clinical test in a sparse landscape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOVi03WUl2UzktVVQtZEdwZjNBNHhKOEFvZ3V0amtXMDRDY2w2NHFzUFhaREF6WE9wWVBRTUZ3YjAxYzllMk9GUGRlU2tqSFhDSFNSX1A3YUVaT0lJMmVTckFjblprUXZXR1VIbXZVRDRkY0NlMjhsWDhqaG5KQ3dyX1pIdFM5eTZzZm9GRUtjTTJHRHMzY3ZteDlobUR1U0pBYVBoRVFyUFk1dWl2S2EzTFpB?oc=5","date":"2022-06-24","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022 - European Medicines A","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":7,"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}